Psychoactive Research chemicals are new synthetic substances that are structurally similar to the original drug, while being functional analogs. Research on the effects of, and treatment for, abuse of these drugs is limited due to the fact that they’re fairly new and have avoided mainstream notice. Research chemicals do not have a lot of human consumption data, and thus harm-reduction and special care should be taken if choosing to ingest them.
Psychedelics are drugs which cause profound changes in a one’s perceptions of reality, otherwise known as hallucinations. While under the influence of hallucinogens, users might see images, hear sounds or feel sensations. These chemicals offer some of the most intense psychological experiences and care should be taken when ingesting them.
This is a commonly used substance with well known and widely available human consumption data. This does not guarantee that the substance will be safe. The safety profile has been established based on usage data commonly available.
Disclaimer: Psychedelic drugs offer some of the most power and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.
Practice Harm Reduction. Proceed with Caution.
Also known as:
xy-4-methylphenyl)-[German][ACD/IUPAC Name] 2-propanamin
xy-4-methylphenyl)-[ACD/IUPAC Name] 2-propanamine
xy-4-méthylphényl)-[French][ACD/IUPAC Name] 2-propanamine
2,5-dimethoxy-α,4-d[ACD/Index Name] imethyl-, (αR)-
oxy-4-methyl-phenyl )-1-methyl-ethyl]am ine
The most popular psychedelic amphetamine due to its pleasant effects, lower potency and shorter duration. Effects have been described as ‘sillier’ than LSD and related DOX chemicals
DOM is a member of the DOx family of compounds which are known for their high potency, long duration, and mixture of psychedelic and stimulant effects. It produces its effects by acting on serotonin receptors in the brain. DOM was first synthesized and tested in 1963 by Alexander Shulgin.
It attained some popularity during the summer of 1967 under the name “STP” (“Serenity, Tranquility, and Peace”), but its use was short-lived due to its side effects. In 1991, the synthesis and pharmacology of DOM was published in Shulgin’s book PiHKAL (“Phenethylamines I Have Known And Loved”). .
Over the years, DOM has gained a reputation for being a highly dose-sensitive psychedelic that is often sold on blotting paper and known for its strong visuals, body load and neutral, analytical headspace. Many reports also indicate that the effects of this chemical may be overly difficult to use for those who are not already experienced with psychedelics.
DOM is part of the so-called "magical half-dozen" which refers to Shulgin's self-rated most important phenethylamine compounds, all of which except mescaline he developed and synthesized himself. They are found within the first book of PiHKAL and are as follows: Mescaline, DOM, 2C-B, 2C-E, 2C-T-2 and 2C-T-7. In mid-1967, tablets containing 20 mg (later 10 mg) of DOM were widely distributed in the Haight-Ashbury District of San Francisco under the name of "STP" (short for "Serenity, Tranquility, and Peace"). This short-lived appearance of DOM on the black market proved disastrous for several reasons.
First, the tablets contained an excessively high dose of the chemical. This, combined with DOM’s slow onset of action (which encouraged some users, familiar with substances that have quicker onsets, such as LSD, to re-dose) and its remarkably long duration, caused many users to panic and sent some to the emergency room. Second, treatment of such overdoses was complicated by the fact that it was unknown at the time that the tablets called “STP” were DOM.
Amphetamines are substituted phenethylamines containing a phenyl ring bound to an amino (NH2) group through an ethyl chain and a methyl group bound to the alpha carbon Rα.
DOM contains methoxy functional groups (OCH3) attached to carbons R2 and R5 and a methyl group attached to carbon R4 of the phenyl ring. DOM is the amphetamine analogue of the phenethylamine 2C-D.
|Avg. Mass||209.2848 Da|
|Monoisotopic Mass||209.141586 Da|
|DOM Duration Data|
Interactions and Synergies
- The 5-MeO class of tryptamines can be unpredictable in their interactions, particularly increasing the risk of unpleasant physical side effects.
- Cannabis has an unexpectedly strong and somewhat unpredictable synergy with psychedelics.
- As an NMDA antagonist MXE potentiates DOx which can be unpleasantly intense
- The combined stimulating effects of the two can be uncomfortable. Coming down on the MDMA while the DOx is still active can be quite anxiogenic.
- High doses of caffeine may cause anxiety which is less manageable when tripping, and since both are stimulating it may cause some physical discomfort.
- MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably
- The DOx class as psychedelic stimulants have the potential to mask the effects of DXM and could lead to redosing to an unsafe level. DXM can also potentiate DOx resulting in an unpleasantly intense experience.
- Details of this combination are not well understood but PCP generally interacts in an unpredictable manner.
- The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of amphetamine can easily lead to thought loops. Coming down from amphetamines while the DOx is still active can be quite anxiogenic.
- The combined stimulating effects of the two can lead to an uncomfortable body-load, while the focusing effects of cocaine can easily lead to thought loops. Coming down from cocaine while the DOx is still active can be quite anxiogenic
- Tramadol is well known to lower seizure threshold and psychedelics also cause occasional seizures.
- Drinking on stimulants is risky because the sedative effects of the alcohol are reduced, and these are what the body uses to gauge drunkenness. This typically leads to excessive drinking with greatly reduced inhibitions, high risk of liver damage and increased dehydration. They will also allow you to drink past a point where you might normally pass out, increasing the risk.
- No unexpected interactions.
|Effects||visual distortions, a 'stoned' feeling, sense of well being.|
|Avoid||marijuana (Can potentiate effects)|
|Marguis Test Result|
|Detection||DOM is a substituted amphetamine, so it can cause you to test positive for amphetamines 3 to 7 days after dosing.|
DOM is a selective partial agonist at the 5-HT2 receptor family. Its psychedelic effects are mediated by its agonistic properties at the 5-HT2A and 5-HT2B receptors, but less so on the 5-HT2C receptor. Due to its selectivity, DOM is often used in scientific research when studying the 5-HT2 receptor subfamily. DOM is a chiral molecule, and R-(-)-DOM is the more active enantiomer, functioning as a potent agonist of the serotonin family of receptors (mainly of the 5-HT2 subtype). However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
User reports suggest that DOM is relatively clear-headed and absent of side-effects in comparison to DOC or DOB. Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation - In terms of its effects on the physical energy levels of the user, DOM is usually considered to be mildly stimulating at levels which do not become overwhelming, encouraging users to move around, run, dance, climb and generally engage in physical activities. In comparison, it is more stimulating than psychedelics like psilocin, but less stimulating than most compounds of the DOx family.
- Spontaneous bodily sensations - The "body high" of DOM is reported to be somewhat intense in comparison to most classical psychedelics. However, in comparison to DOC and the overwhelming forcefulness of 2C-E, it can be considered relatively mild and natural in feel. The sensation itself can be described as a constantly present yet somewhat mild energetic pins and needles sensation that encompasses one's entire body. This is coupled with a euphoric, fast-moving, sharp and location specific tingling sensation. It is usually felt over every square inch of the skin, but occasionally manifests itself in the form of a continuously shifting tingling sensation that travels up and down the body in spontaneous waves.
- Tactile enhancement - Feelings of enhanced tactile sensation are consistently present at moderate levels throughout most DOM experiences. If Level 8A visuals are reached, an intense sensation of suddenly becoming aware of and being able to feel every single nerve ending across a person's entire body all at once is consistently present.
- Bodily control enhancement
- Bodily pressures
- Increased heart rate
- Increased blood pressure
- Temperature regulation suppression
- Increased bodily temperature
- Increased perspiration
- Muscle contractions
- Muscle spasms
- Muscle cramps
- Nausea - Mild to extreme nausea is typically reported at moderate to high dosages and either passes once the user has vomited or gradually fades by itself as the peak sets in.
- Appetite suppression
- Vasoconstriction - This effect is usually only present at higher dosages, but can be particularly uncomfortable and persistent.
- Increased salivation
- Pupil dilation
- Teeth grinding
The cognitive effects of DOM are described by many as a combination of prominent mental stimulation and a powerful enhancement of a person's current mental state.
- Analysis enhancement
- Empathy, love, and sociability enhancement - This component is consistently manifested only in the context of social settings in which one is within the company of others. These feelings of sociability, love and empathy are a little weaker and less sharp than those found on substances such as MDMA and 2C-B, but still prove strong enough to provide long-lasting therapeutic effects.
- Conceptual thinking
- Emotion enhancement
- Immersion enhancement
- Novelty enhancement
- Increased music appreciation
- Memory suppression
- Ego death - While DOM is technically able to produce states of ego dissolution, it tends to more often than not develop only in extremely high doses, with grave physical and mental side effects being apparent and is often of a terrifying nature.
- Personal bias suppression
- Thought acceleration
- Thought connectivity
- Time distortion
Reports describe DOM as having less pronounced visuals proportional to it's accompanying physical and mental effects at low to moderate dosages. Higher ones do tend to display a unique set of visual effects which is not found with similar substances.
- Drifting (melting, flowing, breathing and morphing) - In comparison to other psychedelics, this effect can be described as highly detailed, slow and smooth in motion, static in appearance and unrealistic/cartoon-like in style.
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
- Scenery slicing
The visual geometry of DOM is described as being very unique and may share some similarity with 2C-D. It can be comprehensively described through its variations as intricate in style, equally algorithmic and abstract in form, equally synthetic and organic in style, structured in organization, brightly lit in lighting, multicolored in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in-depth and consistent in intensity. Higher dosages are significantly more likely to result in states of level 8A visual geometry over level 8B.
DOM produces a full range of high-level hallucinatory states in a fashion that is more or less consistent and reproducible than that of many other commonly used psychedelics. These effects include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - In comparison to other psychedelics such as LSD, DOM is extremely high in its internal hallucinations when approaching higher dosages. This particular effect commonly contains hallucinations with scenarios, settings, concepts and autonomous entity contact. They can be comprehensively described in terms of their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability and geometry-based in appearance. They are more common within dark environments and can be described as internal in their manifestation, lucid in believability, interactive in style and almost exclusively of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- Synaesthesia - In its fullest manifestation, this is a very rare and non-reproducible effect. Increasing the dosage can increase the likelihood of this occurring, but seems to only be a prominent part of the experience among those who are already predisposed to synaesthetic states.
Transpersonal states on DOM are reported to occur less reliably and consistently than classical psychedelics. This can perhaps be attributed its the prominent physical and stimulating effects, which tends to interfere with the user's ability to fully immerse themselves in the experience.
Internationally, mescaline is part of the the Convention on Psychotropic Substances of 1971 as a Schedule I substance.
- Shulgin, Alexander (1991). PiHKAL: A Chemical Love Story. Berkeley, CA: Transform Press. pp. 53–56.
- "STP's faster, here's why". Berkeley Barb, June 16-22, 1967. 3-5 (Independent Voices) | http://voices.revealdigital.com/cgi-bin/independentvoices?a=d&d=BFBJFGD19670616.1.3
- Sanders-Bush, Burris, KD; Knoth, K, (September 1988). "Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis" http://www.ncbi.nlm.nih.gov/pubmed/2843634
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089
- "CONVENTION ON PSYCHOTROPIC SUBSTANCES 1971" (PDF). United Nations. Retrieved December 10, 2019.
- New Psychoactive Substances (National Drug and Alcohol Research Centre 2014) | https://comorbidity.edu.au/sites/default/files/cre/page/New Psychoactive Substances.pdf
- Controlled Drugs and Substances Act, Statutes of Canada (1996), c. C-19). Item 19.3. 
- "Fünfte Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086
- 1717 CheMall OR141212
- ABI Chemicals AC1Q56BH
- ABI Chemicals AC2A03J5F
- AKos AKOS022796985
- Alfa Chemistry 15588-95-1
- Alfa Chemistry ACM15588951
- American Custom Chemicals Corp CHM0008084
- Aurora Fine Chemicals A07.500.259
- Aurora Fine Chemicals K18.938.745
- Cayman Chemical 11145
- Cayman Chemical 11145.0
- Cayman Chemical 15703
- Cayman Chemical 15703.0
- ChEMBL CHEMBL8600
- ChemIDplus 015588951
- ChemIDplus 15588951
- ChemIDplus 43061138
- ChemIDplus 43061149
- Chemspace CSC010102381
- Collaborative Drug Discovery 41437
- CSDeposition Service DB01528
- DiscoveryGate 85875
- DrugBank DB01528
- eNovation Chemicals D118098
- EPA DSSTox DTXCID20197305
- FDA UNII - NLM UKI9MLD5OI
- FDA UNII - NLM UNII: UKI9MLD5OI
- Guide to PHARMACOLOGY 164
- Jean-Claude Bradley Open Melting Point Dataset 24243
- LabNetwork LN01325038
- LeadScope LS-103293
- MassBank JP002802
- MassBank WA002881
- MassBank WA002882
- MassBank WA002883
- MassBank WA002884
- MassBank WA002885
- Mcule MCULE-9310533628
- MuseChem M084508
- NIST Chemistry WebBook 3270009793
- NIST Chemistry WebBook 3824853200
- NIST Spectra mainlib_248090
- NIST Spectra nist ri
- NIST Spectra replib_246193
- NIST Spectra replib_335446
- NIST Spectra replib_9631
- Parchem – fine & specialty chemicals 60065
- PubChem 85875
- PubMed 103677
- PubMed 10418794
- PubMed 1056857
- PubMed 10638639
- PubMed 11110193
- PubMed 11420094
- PubMed 1149803
- PubMed 116288
- PubMed 11701202
- PubMed 11900766
- PubMed 11900809
- PubMed 1197576
- PubMed 1208624
- PubMed 1208758
- PubMed 1208759
- PubMed 12106599
- PubMed 12113827
- PubMed 12135540
- PubMed 12164258
- PubMed 12218512
- PubMed 1223994
- PubMed 12376156
- PubMed 1244761
- PubMed 12543238
- PubMed 12753068
- PubMed 12873632
- PubMed 12957227
- PubMed 134754
- PubMed 1361990
- PubMed 14614947
- PubMed 1475306
- PubMed 15019576
- PubMed 15972234
- PubMed 16005500
- PubMed 1664072
- PubMed 1665919
- PubMed 17112572
- PubMed 17551320
- PubMed 1772330
- PubMed 1979813
- PubMed 1981873
- PubMed 2105822
- PubMed 2138338
- PubMed 2213559
- PubMed 2252309
- PubMed 2314063
- PubMed 2359025
- PubMed 2360199
- PubMed 2510097
- PubMed 26578
- PubMed 2707301
- PubMed 2843634
- PubMed 2896360
- PubMed 2901488
- PubMed 2908015
- PubMed 2939233
- PubMed 2944129
- PubMed 3096493
- PubMed 3211970
- PubMed 3685066
- PubMed 3743404
- PubMed 3783595
- PubMed 3801984
- PubMed 3858911
- PubMed 3950910
- PubMed 4150941
- PubMed 4261221
- PubMed 4276702
- PubMed 4388198
- PubMed 4392056
- PubMed 4403750
- PubMed 4435028
- PubMed 4477595
- PubMed 4661229
- PubMed 4681210
- PubMed 4777246
- PubMed 4800136
- PubMed 4809263
- PubMed 4845381
- PubMed 4859236
- PubMed 4860952
- PubMed 4998281
- PubMed 5041482
- PubMed 5458353
- PubMed 5505529
- PubMed 5544403
- PubMed 5544404
- PubMed 564751
- PubMed 5666252
- PubMed 5686169
- PubMed 5732494
- PubMed 5732495
- PubMed 5769766
- PubMed 5778154
- PubMed 6120791
- PubMed 6122729
- PubMed 6136619
- PubMed 6258178
- PubMed 6482668
- PubMed 6483939
- PubMed 6513725
- PubMed 6573879
- PubMed 657412
- PubMed 6581313
- PubMed 6593750
- PubMed 6617740
- PubMed 6655557
- PubMed 6694110
- PubMed 6737421
- PubMed 6770411
- PubMed 6771804
- PubMed 687391
- PubMed 6973157
- PubMed 7243838
- PubMed 7243840
- PubMed 7265116
- PubMed 7291270
- PubMed 731434
- PubMed 7365752
- PubMed 7411554
- PubMed 8160305
- PubMed 8355253
- PubMed 836489
- PubMed 839411
- PubMed 8429622
- PubMed 845874
- PubMed 903913
- PubMed 928488
- PubMed 9423935
- PubMed 9476990
- PubMed 9586861
- PubMed 9649961
- Springer Nature 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement
- Springer Nature 5HT-2 mediation of acute behavioral effects of hallucinogens in rats
- Springer Nature A characteristic effect of hallucinogens on investigatory responding in rats
- Springer Nature A comparison of the discriminative stimulus properties of R-2,5-dimethoxy-4-methylamphetamine (R-DOM) and S-amphetamine in the rat
- Springer Nature Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors
- Springer Nature An hallucinogenic amphetamine analog (DOM) in man
- Springer Nature Assessment of tolerance to the hallucinogenic effects of DOM
- Springer Nature Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function
- Springer Nature Behavioral and neuropharmacological analysis of amphetamine and 2,5-dimethoxy-4-methylamphetamine in rats
- Springer Nature Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinoginic drugs
- Springer Nature Comparison of the discriminative stimulus effects of dimethyltryptamine with different classes of psychoactive compounds in rats
- Springer Nature Cross-reactivities of 39 new amphetamine designer drugs on three abuse drugs urinary screening tests
- Springer Nature Cross-reactivities of 41 new amphetamine designer drugs to EMIT?? immunoassays
- Springer Nature Discriminative stimulus effects of N,N-diisopropyltryptamine
- Springer Nature Discriminative stimulus properties of pizotifen maleate (BC105): a putative serotonin antagonist
- Springer Nature Dissociation of multiple effects of acute LSD on exploratory behavior in rats by ritanserin and propranolol
- Springer Nature Effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) and quipazine on heroin self-administration in rhesus monkeys
- Springer Nature Effects of 5HT-1A agonists on locomotor and investigatory behaviors in rats differ from those of hallucinogens
- Springer Nature Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat
- Springer Nature Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
- Springer Nature Interactions of metergoline with diazepam, quipazine, and hallucinogenic drugs on a conflict behavior in the rat
- Springer Nature Interactive effects of mGlu5 and 5-HT2A receptors on locomotor activity in mice
- Springer Nature LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
- Springer Nature MDA and DOM: Substituted amphetamines that do not produce amphetamine-like discriminative stimuli in the rat
- Springer Nature Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro
- Springer Nature Mescaline: excitatory effects on acoustic startle are blocked by serotonin2 antagonists
- Springer Nature Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors
- Springer Nature Preparation of N-[11C]methyl-2,5-dimethoxy-4-methylamphetamine
- Springer Nature Quantitative analysis of phenethylamine derivatives by thin layer chromatography. Determination of psychotropic drugs and ephedra bases
- Springer Nature Relative potency of amphetamine derivatives and N,N-dimethyltryptamines
- Springer Nature Role of 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives
- Springer Nature Role of intracellular Ca2 signaling in the antinociceptive and discriminative stimulus effects of the imidazoline I2 receptor agonist 2-BFI in rats
- Springer Nature Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon
- Springer Nature Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli
- Springer Nature Some effects of the hallucinogenic drug 2,5-dimethoxy-4-methyl amphetamine on the metabolism of biogenic amines in the rat brain
- Springer Nature The action of tryptamine on the dog spinal cord and its relationship to the agonistic actions of LSD-like psychotogens
- Springer Nature The discriminative stimulus properties of 2,5-dimethoxy-4-methylamphetamine (DOM): Differentiation from amphetamine
- Springer Nature The effects of 2,5-dimethoxy-4-methylamphetamine (DOM), 2,5-dimethoxy-4-ethylamphetamine (DOET), d-amphetamine, and cocaine in rats trained with mescaline as a discriminative stimulus
- Springer Nature The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs I: Antagonist correlation analysis
- Springer Nature The time-dependent stimulus effects of R(-)-2,5-dimethoxy-4-methamphetamine (DOM): implications for drug-induced stimulus control as a method for the study of hallucinogenic agents
- The Merck Index Online cs000000007710
- Thomson Pharma 00485877
- VulcanChem VC203073
- Wikipedia 2,5-dimethoxy-4-methylamphetamine
- xPharm 7725
Information made possible with:
- PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
- Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
- PubChem National Center for Bio Informatics
- Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
Additional APIs were used to construct this information. Thanks for ChemSpider, NCBI, PubChem etc.
Data is constantly updated so please check back later to see if there is any more available information on this substance.